Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab
PHASE2
The primary objective of this study is to determine the clinical performanc...
Status
Unknown
Location
Universitätsklinikum Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
PHASE1
This study will characterize the safety and tolerability and identify the r...